Effects of glibenclamide on systemic and splanchnic haemodynamics in conscious rats. 1994

R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
Laboratoire d'Hémodynamique Splanchnique, Unité de Recherches de Physiopathologie Hépatique, INSERM U-24, Hôpital Beaujon, Clichy, France.

1. The effects of the sulphonylurea, glibenclamide (20 mg kg-1, i.v.), at a dose that blocks vascular potassium channels, on systemic and splanchnic haemodynamics (radioactive microspheres) were studied in conscious rats. 2. Glibenclamide significantly decreased cardiac index and hepatic artery blood flow while it significantly increased vascular resistance in systemic, portal and hepatic arterial territories. 3. In rats with suppressed cardiovascular reflexes, glibenclamide induced vasoconstriction in systemic, portal and hepatic arterial territories. 4. Intracerebroventricular administration of glibenclamide did not alter systemic or regional vascular tone. 5. Glibenclamide blunted the vasodilator effect of the potassium channel opener, diazoxide but not that of the L-type calcium channel blocker, nicardipine. 6. Another sulphonylurea, glipizide (20 mg kg-1, i.v.), induced significant systemic and splanchnic vasoconstriction. 7. Thus, the glibenclamide-induced blockade of vascular potassium channels caused a vasoconstriction in the systemic and splanchnic vascular beds. In these territories, therefore, the opening of glibenclamide-sensitive potassium channels might be responsible for a basal vasodilator tone.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D009529 Nicardipine A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. Antagonil,Cardene,Cardene I.V.,Cardene SR,Dagan,Flusemide,Lecibral,Lincil,Loxen,Lucenfal,Nicardipine Hydrochloride,Nicardipine LA,Nicardipino Ratiopharm,Nicardipino Seid,Perdipine,Ridene,Vasonase,Y-93,Hydrochloride, Nicardipine,LA, Nicardipine,Y 93,Y93
D003345 Corticosterone An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
D003981 Diazoxide A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. Hyperstat,Proglycem
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013152 Splanchnic Circulation The circulation of blood through the BLOOD VESSELS supplying the abdominal VISCERA. Mesenteric Circulation,Circulation, Mesenteric,Circulation, Splanchnic,Circulations, Mesenteric,Circulations, Splanchnic,Mesenteric Circulations,Splanchnic Circulations
D014661 Vasoconstriction The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE. Vasoconstrictions

Related Publications

R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
July 1989, Journal of hepatology,
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
May 2007, Experimental physiology,
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
May 1985, Clinical science (London, England : 1979),
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
January 1989, British journal of clinical pharmacology,
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
December 1991, Clinical science (London, England : 1979),
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
April 1995, Journal of hepatology,
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
January 1998, Cytokine,
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
May 1997, Journal of hepatology,
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
November 1989, Clinical science (London, England : 1979),
R Moreau, and H Komeichi, and P Kirstetter, and S Yang, and B Aupetit-Faisant, and S Cailmail, and D Lebrec
March 1991, Acta physiologica Scandinavica,
Copied contents to your clipboard!